Physician profile
Dean A Smith
NPI 1811963390
$6,638.09
in general payments reported to CMS, 2019-2025
49 companies · $907 in 2025
The $907 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $871 · 2021: $1,528 · 2022: $892 · 2023: $623 · 2024: $826 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,356.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $625.28 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $545.08 | 2019-2022 | |
| Amarin Pharma, INC. | $541.82 | 2019-2022 | |
| Abbvie INC. | $395.93 | 2021-2025 | Vraylar, Qulipta |
| Kowa Pharmaceuticals America, INC. | $348.49 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $339.25 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $336.96 | 2019-2025 | |
| Amgen INC. | $309.05 | 2019-2025 | Repatha, Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $286.29 | 2019-2024 | Trintellix |
| Astrazeneca Pharmaceuticals Lp | $277.03 | 2019-2025 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $246.94 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $226.58 | 2019-2025 | |
| Astellas Pharma US INC | $218.65 | 2019-2025 | Veozah, Myrbetriq |
| Medtronic, INC. | $158.95 | 2023-2025 | Interstim, Intellis Adaptivestim, Inceptiv |
| Merck Sharp & Dohme LLC | $145.00 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.